• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Rhythm Pharmaceuticals Inc.

    2/28/25 4:00:58 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RYTM alert in real time by email
    S-8 1 tmb-20250228xs8.htm S-8

    As filed with the Securities and Exchange Commission on February 28, 2025

    Registration No. 333-

    ​

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    ​

    Rhythm Pharmaceuticals, Inc.

    (Exact name of Registrant as specified in its charter)

    ​

    Delaware

       

    46-2159271

    (State or other jurisdiction of

    Incorporation or organization)

    ​

    (I.R.S. Employer

    Identification No.)

    ​

    222 Berkeley Street

    12th Floor

    Boston, MA 02116

    (857) 264-4280

    (Address of principal executive offices) (Zip code)

    ​

    Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan

    (Full title of the plan)

    ​

    David P. Meeker, M.D.

    Chief Executive Officer, President and Chairman of the Board

    Rhythm Pharmaceuticals, Inc.

    222 Berkeley Street

    12th Floor

    Boston, MA 02116

    (857) 264-4280

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

    ​

    With copies to:

    Peter N. Handrinos, Esq.

    Latham & Watkins LLP

    John Hancock Tower

    200 Clarendon Street

    Boston, MA 02116

    (617) 948-6060

    ​

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    ​

    Large accelerated filer ☒

    Accelerated filer ☐

     

     

    Non-accelerated filer ☐ 

    Smaller reporting company ☐

     

     

     

    Emerging growth company ☐ 

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for comply with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

    ​

    ​

    ​


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 2,495,626 shares of the Registrant’s common stock to be issued pursuant to the Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan (the “Incentive Plan”). A Registration Statement of the Registrant on Form S-8 relating to the Incentive Plan is effective.

    INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENTS ON FORM S-8

    The contents of the Registration Statements on Form S-8 (File Nos. 333-220925, 333-223647, 333-229642, 333-236829, 333-253709, 333-263168, 333-270231 and 333-277539), including any amendments thereto, filed with the Securities and Exchange Commission, relating to the Incentive Plan, are incorporated herein by reference.

    ​

    Item 8.

    Exhibits

    ​

    ​

    ​

    ​

    Exhibit
    Number

       

    Description

    ​

    ​

    ​

    4.1

     

    Amended and Restated Certificate of Incorporation of Rhythm Pharmaceuticals, Inc., dated October 10, 2017 (incorporated by reference to Exhibit 3.1 to Rhythm Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q (File No. 001-38223) filed on May 4, 2020)

    ​

    ​

    ​

    4.2

    ​

    Amended and Restated Certificate of Designations of Rhythm Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.4 to Rhythm Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q (File No. 001 38223) filed on May 7, 2024)

    ​

    ​

    ​

    4.3

     

    Amended and Restated Bylaws of Rhythm Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to Rhythm Pharmaceuticals, Inc.’s Current Report on Form 8-K (File No. 001-38223) filed on December 18, 2023)

     

     

    ​

    5.1*

     

    Opinion of Latham & Watkins LLP

     

     

    ​

    23.1*

     

    Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm

     

     

    ​

    23.2*

     

    Consent of Latham & Watkins LLP (included in Exhibit 5.1)

     

     

    ​

    24.1*

     

    Power of Attorney (included on signature page)

     

     

     

    99.1

     

    Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan and Form of Option Agreement (incorporated by reference to Exhibit 10.2 to Rhythm Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q (File No. 001-38223) filed on November 14, 2017)

     

     

     

    99.2

     

    2017 Equity Incentive Plan Form of Restricted Stock Unit Award Agreement (incorporated by reference to Exhibit 10.18 to Rhythm Pharmaceuticals, Inc.’s Annual Report on Form 10-K (File No. 001-38223) filed on March 2, 2020)

    ​

    ​

    ​

    99.3

    ​

    2017 Equity Incentive Plan Performance Unit Agreement (incorporated by reference to Exhibit 10.4 to Rhythm Pharmaceuticals, Inc.’s Quarterly Report on Form 10 Q (File No. 001 38223) filed on May 7, 2024)

     

     

     

    107.1*

     

    Filing Fee Table


    *

    Filed herewith.

    ​


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on February 28, 2025.

    RHYTHM PHARMACEUTICALS, INC.

     

    By:

    /s/ David P. Meeker, M.D.

     

    David P. Meeker, M.D.

     

    Chief Executive Officer, President and

     

    Chairman of the Board

    ​

    ​

    POWER OF ATTORNEY

    Each person whose signature appears below hereby constitutes and appoints David P. Meeker, M.D. and Hunter C. Smith, or each of them singly, with full power to act without the other, such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this registration statement and any and all amendments, including post-effective amendments to this registration statement, and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary or desirable to be done in connection therewith as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.


    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

    Signature

       

    Title

       

    Date

     

     

     

     

     

    /s/ David P. Meeker, M.D.

     

    Chief Executive Officer, President and Director

     

    February 28, 2025

    David P. Meeker, M.D.

     

    (Principal Executive Officer)

     

     

     

     

     

     

     

    /s/ Hunter C. Smith

     

    Chief Financial Officer

     

    February 28, 2025

    Hunter C. Smith

     

    (Principal Financial Officer)

     

     

     

     

     

     

     

    /s/ Christopher P. German

     

    Vice President, Corporate Controller

     

    February 28, 2025

    Christopher P. German

     

    (Principal Accounting Officer)

     

     

     

     

     

     

     

    /s/ Edward T. Mathers

     

    Lead Director

     

    February 28, 2025

    Edward T. Mathers

     

     

     

     

     

     

     

     

     

    /s/ Stuart Arbuckle

     

    Director

     

    February 28, 2025

    Stuart Arbuckle

     

     

     

     

     

     

     

     

     

    /s/ Camille L. Bedrosian, M.D.

     

    Director

     

    February 28, 2025

    Camille L. Bedrosian, M.D.

     

     

     

     

     

     

     

     

     

    /s/ Jennifer L. Good

     

    Director

     

    February 28, 2025

    Jennifer L. Good

     

     

     

     

     

     

     

     

     

    /s/ Christophe R. Jean

     

    Director

     

    February 28, 2025

    Christophe R. Jean

     

     

     

     

     

     

     

     

     

    /s/ David W. J. McGirr

     

    Director

     

    February 28, 2025

    David W. J. McGirr

     

     

     

     

     

     

     

     

     

    /s/ Lynn A. Tetrault, J.D.

     

    Director

     

    February 28, 2025

    Lynn A. Tetrault, J.D.

     

     

     

     

    ​


    Get the next $RYTM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RYTM

    DatePrice TargetRatingAnalyst
    4/7/2025$63.00Neutral → Buy
    BofA Securities
    3/5/2025$78.00Buy
    Stifel
    1/2/2025$80.00Buy
    Jefferies
    12/20/2024$76.00Outperform
    Oppenheimer
    10/21/2024$70.00Buy
    Guggenheim
    9/18/2024$64.00Buy
    H.C. Wainwright
    9/17/2024$64.00Mkt Outperform
    JMP Securities
    5/8/2024$49.00 → $42.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $RYTM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Rhythm Pharmaceuticals Inc.

      SC 13G - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

      11/14/24 9:50:26 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rhythm Pharmaceuticals Inc.

      SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

      11/14/24 5:46:11 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rhythm Pharmaceuticals Inc.

      SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

      11/12/24 5:23:38 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    SEC Filings

    See more
    • SEC Form 10-Q filed by Rhythm Pharmaceuticals Inc.

      10-Q - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)

      5/7/25 4:46:19 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)

      5/7/25 7:01:40 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Rhythm Pharmaceuticals Inc.

      DEFA14A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)

      4/29/25 4:01:46 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

      -- First quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity -- -- U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity on track to be completed in the third quarter of 2025 -- -- Topline data from Phase 2 trial of oral MC4R agonist bivamelagon on track to be announced in third quarter of 2025 -- -- Cash on-hand expected to support planned operations into 2027 -- -- Management to host conference call today at 8:00 a.m. ET -- B

      5/7/25 7:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

      BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at three upcoming investor conferences: Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025 at 12:20 a.m. ETJefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 3:10 p.m. ETGoldman Sachs Annual Healthcare Conference on Monday, June 9, 2025 at 8:00 a.m. ET The fireside chats will be webcasted and availab

      5/6/25 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

      BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 7, 2025 to report its first quarter 2025 financial results and provide a corporate update. To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. A webcast of the call will also be available under "Events and Presentations" in the Invest

      4/23/25 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    Leadership Updates

    Live Leadership Updates

    See more
    • Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer

      BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair "Al" Garfield, Ph.D. as Chief Scientific Officer, effective July 1. "We are excited to welcome Al back to Rhythm as we continue to leverage our understanding of the melanocortin-4 receptor (MC4R) pathway to bring potential therapies to patients and their families," said David Meeker, M.D., Rhythm Chairman, Chief Executive Officer and President. "Al's leadership and established scientific expertise and experience

      7/8/24 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

      BOSTON, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced the appointment of Dana Washburn, M.D., as Senior Vice President of Clinical Development and as a member of the Company's Executive Leadership Team, effective September 26, 2022. As SVP of Clinical Development, Dr. Washburn will lead the Company's robust clinical development program, clinical operations, and data management. "Dr. Washburn is a collaborative, resourceful leade

      10/6/22 4:02:00 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wren Appoints Bart Henderson as Chief Executive Officer

      Wren Therapeutics, a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, today announced the appointment of Bart Henderson as Chief Executive Officer. Wren's unique drug discovery platform harnesses advances in the biophysics of protein assembly dynamics to target the toxic fleeting protein intermediates, the oligomers, in neurodegenerative disease pathways, and discover small molecules that can block their generation with precision. Bart brings broad leadership experience in the biotechnology industry as a founder and co-founder of several companies including Torque (now Repertoire Immune Medicines), Rhythm (NASDAQ:RYTM) and its subsidiary Motus (acquired

      3/4/22 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rhythm Pharmaceuticals upgraded by BofA Securities with a new price target

      BofA Securities upgraded Rhythm Pharmaceuticals from Neutral to Buy and set a new price target of $63.00

      4/7/25 12:20:34 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel resumed coverage on Rhythm Pharmaceuticals with a new price target

      Stifel resumed coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $78.00

      3/5/25 7:44:16 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Rhythm Pharmaceuticals with a new price target

      Jefferies initiated coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $80.00

      1/2/25 8:06:46 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Human Resources Officer Cramer Pamela J. sold $457,663 worth of shares (7,031 units at $65.09) and exercised 7,031 shares at a strike of $6.80 (SEC Form 4)

      4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

      5/1/25 4:53:44 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Head of International Mazabraud Yann sold $438,946 worth of shares (6,745 units at $65.08), decreasing direct ownership by 15% to 37,655 units (SEC Form 4)

      4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

      5/1/25 4:52:53 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Head of International Mazabraud Yann converted options into 21,780 shares, increasing direct ownership by 96% to 44,400 units (SEC Form 4)

      4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

      4/16/25 4:30:22 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    Financials

    Live finance-specific insights

    See more
    • Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

      -- First quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity -- -- U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity on track to be completed in the third quarter of 2025 -- -- Topline data from Phase 2 trial of oral MC4R agonist bivamelagon on track to be announced in third quarter of 2025 -- -- Cash on-hand expected to support planned operations into 2027 -- -- Management to host conference call today at 8:00 a.m. ET -- B

      5/7/25 7:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

      BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 7, 2025 to report its first quarter 2025 financial results and provide a corporate update. To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. A webcast of the call will also be available under "Events and Presentations" in the Invest

      4/23/25 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

      -- Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks (p<0.0001) -- -- -19.2% placebo-adjusted BMI reduction achieved in adult patients 18 years old and older (n=49) at 52 weeks -- -- -20.2% placebo-adjusted BMI reduction achieved in patients younger than 18 years old (n=71) at 52 weeks -- -- Regulatory submissions in the U.S. and EU anticipated to be completed in the third quarter of 2025 -- -- Company to host conference call today at 8 a.m. ET -- BOSTON, April 07, 2025 (GLOBE NEWSWIRE) --  Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage bi

      4/7/25 7:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care